Vivos Therapeutics, Inc. - VVOS STOCK NEWS

Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.

Vivos Therapeutics, Inc. (symbol: VVOS) is a leading medical technology company dedicated to providing innovative solutions for patients suffering from sleep disordered breathing (SDB), particularly mild-to-moderate obstructive sleep apnea (OSA). The company specializes in the development and commercialization of proprietary treatment protocols and customized oral appliances, known collectively as the Vivos System. This non-surgical, non-invasive, and non-pharmaceutical system is designed to address craniofacial and anatomical anomalies associated with OSA, offering a cost-effective alternative to traditional treatments.

The Vivos System combines the expertise of specially trained dentists and medical professionals to deliver comprehensive care. Through its Vivos Integrated Healthcare Network, the company enables healthcare providers, including general dentists, medical doctors, myofunctional therapists, and chiropractors, to offer targeted therapies for SDB. Additionally, Vivos licenses its intellectual property to third-party manufacturers to fabricate these advanced appliance devices, expanding its reach and impact.

Recent developments at Vivos Therapeutics highlight the company's commitment to improving patient outcomes. The favorable update to United Healthcare's medical policy now endorses oral appliance therapies, potentially increasing the adoption of Vivos devices. Furthermore, the recall of numerous CPAP devices by ResMed and Philips Respironics presents a significant revenue opportunity for Vivos.

The company has also achieved a significant milestone with the introduction of the first Medicare-accepted oral appliance treatment for all severities of obstructive sleep apnea in adults. This breakthrough enhances the accessibility of effective OSA treatment to a broader patient population.

Vivos Therapeutics continues to position itself as a pioneer in the medical technology space, driven by its mission to improve the quality of life for patients with sleep-disordered breathing. Stay informed about Vivos Therapeutics' latest news and developments to understand the dynamic landscape of this innovative company.

11/14/2023 04:05 PM

News

Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update

Rhea-AI Summary

Vivos Therapeutics, Inc. (NASDAQ: VVOS) reported a 32% year-over-year decrease in operating expenses and a 19% sequential decrease. New strategic relationships, including a U.S. nationwide distribution agreement with Lincare, are expected to bring significant new revenue opportunities. The company's cost-cutting measures have led to a 61% reduction in net loss for the third quarter of 2023, and a 47% reduction for the nine months ended September 30, 2023. Vivos also completed a private placement for net proceeds of approximately $3.5 million in November 2023 to augment its liquidity position.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.22%

Tags

11/09/2023 04:30 PM

News

Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call

Rhea-AI Summary

Vivos Therapeutics, Inc. (NASDAQ: VVOS) plans to release its third quarter 2023 financial results after market close on November 14, 2023. The company will conduct a conference call at 5:00 p.m. (Eastern Time) the same day to review the results and provide an overview of recent milestones and developments. Investors can access the conference call via phone or webcast.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-5.84%

Tags

11/02/2023 05:00 PM

News

Vivos Therapeutics Closes $4 Million Private Placement

Rhea-AI Summary

Vivos Therapeutics, Inc. has closed a $4 million private placement, with net proceeds of approximately $3.5 million. The company plans to use the funds for general working capital. In the private placement, Vivos issued 980,393 shares of common stock at a purchase price of $4.08 per share. They also issued a Series A Warrant and a Series B Warrant to purchase additional shares. A.G.P./Alliance Global Partners acted as the sole placement agent for the offering.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-5.52%

Tags

10/31/2023 08:00 AM

News

Vivos Therapeutics Announces Pricing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Rhea-AI Summary

Vivos Therapeutics, Inc. has entered into a securities purchase agreement with an institutional investor for the purchase and sale of 980,393 shares of its common stock at a price of $4.08 per share. Additionally, the investor will receive a five-year Series A Warrant and an eighteen-month Series B Warrant to purchase additional shares of common stock.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-16.19%

Tags

10/26/2023 07:30 AM

News

Vivos Therapeutics Announces Reverse Stock Split

Rhea-AI Summary

Vivos Therapeutics, Inc. will undergo a 1-for-25 reverse stock split of its common stock, effective October 27, 2023. The reverse stock split aims to bring Vivos into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq Capital Market. The number of outstanding shares will be reduced from 29,928,786 shares to approximately 1,197,151 shares. Shareholders with fractional shares will have them rounded up to the nearest whole share. The exercise prices of outstanding options and warrants will be adjusted accordingly. Vivos' transfer agent, VStock Transfer LLC, will handle the exchange process for stockholders.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-6.83%

Tags

10/24/2023 07:30 AM

News

Vivos Therapeutics Signs Nationwide Distribution Agreement with Lincare

Rhea-AI Summary

Vivos Therapeutics signs nationwide distribution agreement with Lincare, a leading supplier of in-home respiratory therapy products and services. Lincare will have a six-month exclusivity to distribute certain designated Vivos devices. This collaboration aims to offer alternative treatment options for sleep apnea patients who discontinue CPAP usage.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-5.76%

Tags

10/11/2023 07:30 AM

News

Vivos Therapeutics to Begin Clinical Trial at Stanford Medicine

Rhea-AI Summary

Vivos Therapeutics announces clinical trial using DNA Oral Appliance Therapy to study impact on OSA versus CPAP

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.63%

Tags

10/05/2023 07:30 AM

News

Vivos Therapeutics Announces Strategic Collaboration in the Middle East-North Africa Region to Support International Expansion

Rhea-AI Summary

Vivos Therapeutics, Inc. has entered into an exclusive distribution agreement with NOUM DMCC, a Dubai-based company, to distribute its products in the Middle East-North Africa region. Noum will seek regulatory approvals for Vivos medical devices and has already scheduled a training event for early 2024. Vivos expects revenue from this collaboration in 2024.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

6.89%

Tags

10/04/2023 07:30 AM

News

Vivos Therapeutics Executes Strategic Agreements with Ormco and On Demand Orthodontist To Provide Spark™ Clear Aligners to Its National Network of Providers

Rhea-AI Summary

Vivos Therapeutics announces two key strategic agreements to expand product line and create additional revenue opportunities

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

64.86%

Tags

10/02/2023 07:30 AM

News

New York Times Best-Selling Author James Nestor to Headline List of Speakers for Fifth Annual Vivos Breathing Wellness Conference

Rhea-AI Summary

Vivos announces Fifth Annual Breathing Wellness Conference with renowned speakers. Vivos-trained dentists to learn about new services and technologies.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.04%

Tags

FAQ

What is the current stock price of Vivos Therapeutics (VVOS)?

The current stock price of Vivos Therapeutics (VVOS) is $5.12 as of December 23, 2024.

What is the market cap of Vivos Therapeutics (VVOS)?

The market cap of Vivos Therapeutics (VVOS) is approximately 22.0M.

What does Vivos Therapeutics, Inc. specialize in?

Vivos Therapeutics specializes in the development and commercialization of technology solutions for patients with sleep disordered breathing, including mild-to-moderate obstructive sleep apnea.

What is the Vivos System?

The Vivos System is a non-surgical, non-invasive treatment for mild-to-moderate obstructive sleep apnea, involving customized oral appliances and proprietary treatment protocols.

Who can benefit from Vivos Therapeutics' solutions?

Patients with mild-to-moderate obstructive sleep apnea (OSA) and related sleep disordered breathing conditions can benefit from Vivos Therapeutics' solutions.

How does Vivos Therapeutics collaborate with healthcare providers?

Vivos Therapeutics collaborates with healthcare providers through its Vivos Integrated Healthcare Network, enabling dentists, medical doctors, and other professionals to offer targeted treatments.

What are some recent achievements of Vivos Therapeutics?

Recent achievements include the favorable update to United Healthcare's policy supporting oral appliance therapies and the introduction of Medicare-accepted oral appliance treatment for all severities of obstructive sleep apnea.

What opportunities have arisen from the recall of CPAP devices?

The recall of CPAP devices by ResMed and Philips Respironics has created significant revenue opportunities for Vivos Therapeutics' oral appliance devices.

How does Vivos Therapeutics manufacture its oral appliances?

Vivos Therapeutics licenses its intellectual property to third-party manufacturers who fabricate the appliance devices for healthcare professionals.

What makes the Vivos System unique?

The Vivos System is unique due to its non-surgical, non-invasive, and non-pharmaceutical approach, offering a cost-effective solution for treating mild-to-moderate obstructive sleep apnea.

Who are the target customers for Vivos Therapeutics?

Target customers include general dentists, medical doctors, myofunctional therapists, chiropractors, and other healthcare providers involved in treating sleep disordered breathing.

What is the mission of Vivos Therapeutics?

The mission of Vivos Therapeutics is to improve the quality of life for patients suffering from sleep disordered breathing through innovative and effective treatment solutions.